US › Healthcare

Adagene Inc (ADAG)

US · Healthcare · Biotechnology

$2.06-14.17%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.6M

Net profit

$-16.4M

EPS estimate

$-0.19

Net margin

-1,011.1%

Key statistics

Market cap

$138.3M

Forward P/E

0.0

P/B

2.21

Book value

$1.33

EPS (TTM)

$-0.38

52-week high

$4.85

52-week low

$1.30

50-day MA

$3.34

200-day MA

$3.39

Beta

0.54

Analyst view

Analysts rate Adagene Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $9.91.

Shareholding

Insiders

11.39%

Institutions

36.04%

Largest institutional holders

Fund	Stake
Jupiter Topco LLC	9.93%
Siren, L.L.C.	3.97%
Deerfield Management Co	3.97%
HSG Holding Ltd	2.00%
Squadron Capital Management LLC	1.86%
Ameriprise Financial Inc	0.91%
Dauntless Investment Group, LLC	0.80%
Citadel Advisors Llc	0.76%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adagene Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.